Phio Pharmaceuticals Corp.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PHIO PHARMACEUTICALS CORP. | |
| By: | /s/ Robert J. Bitterman |
| Robert J. Bitterman | |
| President and Chief Executive Officer (as Principal Executive Officer) | |
| Date: March 31, 2025 |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signatures | Title | Date |
|---|---|---|
| /s/ Robert J. Bitterman Robert J. Bitterman | President, Chief Executive Officer and Director (Principal Executive Officer) | March 31, 2025 |
| /s/ Robert Infarinato Robert Infarinato | Vice President and Chief Financial Officer (Principal Financial Officer) | March 31, 2025 |
| /s/ Patricia Bradford Patricia Bradford | Director | March 31, 2025 |
| /s/ Robert L. Ferrara Robert L. Ferrara | Director | March 31, 2025 |
| /s/ Jonathan E. Freeman Jonathan E. Freeman, Ph.D. | Director | March 31, 2025 |
| /s/ Curtis A. Lockshin Curtis A. Lockshin, Ph.D. | Director | March 31, 2025 |
| /s/ David H. Deming | Director | March 31, 2025 |
| David H. Deming | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.